Victoza Vision Loss Lawsuit

The Victoza vision loss lawsuit category refers to claims alleging that some patients experienced sudden or permanent eye injury after using Victoza (liraglutide).

Victoza is a glucagon like peptide 1 receptor agonist, administered as a liraglutide injection, and prescribed as a diabetes drug to improve glycemic control and help lower blood sugar in type 2 diabetes.

In product labeling, Victoza includes multiple warnings and precautions that are not vision-specific, including risks described in connection with thyroid c cell tumors (including medullary thyroid carcinoma), acute pancreatitis, acute gallbladder disease, and kidney-related events such as acute renal failure and worsening renal impairment.

It also warns about serious allergic reactions and instructs monitoring of renal function in certain clinical contexts.

As of early February 2026, there are at least 37 active vision loss lawsuits grouped in federal court related to GLP-1 medications.

The Judicial Panel on Multidistrict Litigation (JPML) has centralized NAION cases involving GLP-1 receptor agonists in MDL No. 3163 in the Eastern District of Pennsylvania, which is a procedural mechanism intended to coordinate pretrial issues across cases and does not decide causation or liability.

Why Victoza Is Named in the GLP-1 Litigation

The newest GLP-1 lawsuits involving Victoza are the NAION cases.

Those cases are in early stages, with no trials or settlements reported in the centralized proceeding at this point.

Plaintiffs generally allege a temporal association between GLP-1 exposure and optic-nerve injury, while defendants typically dispute causation and raise alternative explanations and risk factors.

The MDL structure exists to manage common pretrial issues such as pleadings, document exchange, and expert-related questions across multiple diabetes medications that share a drug class, including GLP-1 receptor agonists.

Victoza Lawsuit Settlement Amounts: Projections and Estimates

At this time, there have not been public settlements or jury verdicts establishing valuation benchmarks for a Victoza lawsuit based on NAION or other asserted vision-loss injuries.

Lawyers estimate that alleged partial vision-loss claims could be between $300,000 and $750,000 and that alleged total blindness claims could be $500,000 to over $1 million, but those figures are not outcomes and should be treated as informal estimates that may not reflect any eventual results.

Any compensation discussion in active litigation is fact-specific and depends on medical proof, causation evidence, jurisdiction, plaintiff characteristics, and the procedural posture of the case.

So far, there haven’t been any settlements or jury verdicts for any Victoza vision loss lawsuits.

Other Drugs and Manufacturers Named in the GLP-1 Lawsuits

Victoza remains one of the GLP-1 products discussed in federal coordination because it is a receptor agonist used for diabetes management and, in certain patient groups, has been studied in large outcomes trials focused on major cardiovascular endpoints.

Other drugs and manufacturers are named in GLP-1 lawsuits because plaintiffs allege similar injury mechanisms across the drug class, even though each product has its own labeling, indications, and safety data.

Other GLP-1 drugs commonly named in the broader lawsuits include:

• Ozempic (semaglutide)
• Wegovy (semaglutide)
• Trulicity (dulaglutide)
• Rybelsus (oral semaglutide)
• Mounjaro (tirzepatide)
• Zepbound (tirzepatide)

The inclusion of multiple drugs in related proceedings reflects procedural coordination of overlapping allegations, not a finding that any specific product caused a patient’s injury.

Victoza is a diabetes drug (liraglutide injection) in the glucagon like peptide 1 class, also described as a receptor agonist, and it is prescribed to improve glycemic control and lower blood sugar in some patients alongside diet, activity, and sometimes other diabetes medications.

The Victoza prescribing information reports that nausea was the most common adverse reaction in clinical trials, followed by diarrhea and vomiting, including in placebo controlled trial settings.

Some patients also report decreased appetite and weight loss while using GLP-1 products, which is consistent with how this drug class can affect gastric motility and insulin secretion.

The label describes delayed gastric emptying, which can affect the absorption of oral medications.

Injuries and medical conditions referenced in Victoza and broader GLP-1 safety discussions include:

• Nausea
• Diarrhea
• Vomiting
• Severe stomach pain potentially consistent with pancreatitis
• Acute pancreatitis
• Gallbladder disease, including acute gallbladder disease
• Renal impairment, including acute renal failure and chronic renal failure concerns in certain contexts
• Thyroid C cell tumors observed in rodent studies, with labeling contraindications tied to medullary thyroid carcinoma and MEN 2
• Thyroid cancer
• Serious allergic reactions
• Delayed gastric emptying and related gastrointestinal motility effects

Serious adverse reactions described in the Victoza label include acute pancreatitis and acute gallbladder disease, and patients are typically told to seek medical attention for severe stomach pain that may be consistent with pancreatitis.

The label also addresses renal risk, including acute renal failure and worsening renal impairment in some circumstances, with renal function monitoring considerations in patients who develop significant gastrointestinal symptoms that can lead to dehydration.

Victoza also carries a boxed warning regarding thyroid c cell tumors observed in rodents and states that it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.

Vision Loss Potentially Linked to GLP-1 Usage

As to vision loss, current Victoza vision loss lawsuit allegations are being litigated in a federal MDL focused on non-arteritic anterior ischemic optic neuropathy (NAION) claims involving GLP-1 RAs.

The Eastern District of Pennsylvania’s MDL page describes the JPML’s centralization rationale as involving common questions of fact concerning development, testing, regulatory history, labeling, and the products’ alleged capacity to cause NAION.

In these cases, plaintiffs generally allege an association between GLP-1 exposure and vision loss, but the existence of coordinated proceedings does not establish causation and does not reflect a judicial finding on the merits.

Most law firms apply intake criteria before accepting a Victoza case, particularly in claims alleging vision loss such as NAION.

A typical starting point is documented use of Victoza (liraglutide) and a medical record showing an optic-nerve event or vision loss diagnosis after exposure.

Firms also look for a clear timeline, alternative risk factors, and whether the claimed injury is supported by ophthalmology records rather than self-report alone.

The statute of limitations for filing a personal injury claim related to Victoza varies by state and is often described as a two to three year window, measured from an event date or accrual date depending on state law and the claim type.

Missing the applicable filing deadline can bar a civil claim even when the injury is documented.

The first step in filing a Victoza lawsuit is usually a case evaluation, and most law firms offer new clients a free case evaluation to discuss legal options and basic eligibility.

In product liability litigation against Novo Nordisk, a plaintiff generally must prove a defect and causation, meaning the product was defective under the applicable legal theory and that the defect caused the claimed injury.

Evidence Commonly Reviewed in GLP-1 Lawsuits

Evidence review typically focuses on whether the medical record supports the alleged injury and whether the timing of events is consistent with the claimed exposure history.

In GLP-1 cases, documentation is used to confirm product use, rule in the diagnosis, and evaluate other potential explanations reflected in the chart.

Law firms and defense counsel generally assess the same core categories of records when evaluating causation and damages.

Common categories of evidence include:

• Pharmacy records showing Victoza fills and dose history
• Prescribing records and visit notes documenting the indication for use
• Medication lists showing other diabetes medications and relevant comorbidities
• Ophthalmology records, including visual acuity testing, visual field testing, and exam findings
• Imaging and diagnostic studies commonly used in optic-nerve evaluations (for example OCT reports)
• Emergency or hospital records tied to the onset of vision symptoms
• Records reflecting symptom onset date, progression, and treatment timeline
• Prior eye history and baseline eye exams, if available
• Employment and wage documentation if lost income is claimed
• Health insurance explanation-of-benefits records showing billed and paid amounts
• Photographs or written statements supporting functional limitations, when relevant and consistent with medical records

Damages in Victoza Lawsuit Claims

Damages analysis usually begins with documented financial loss, then evaluates whether the record supports longer-term limitations tied to the alleged vision injury.

The categories asserted vary by jurisdiction, the severity of vision impairment, and the extent of medical care required.

Claimed damages are typically supported through billing records, wage documentation, and treating-provider notes addressing functional impact.

Common categories of damages alleged in product cases may include:

• Past medical expenses related to the eye injury evaluation and treatment
• Future medical care costs tied to ongoing ophthalmology follow-up and monitoring
• Prescription costs and assistive devices, including low-vision aids
• Lost wages for time missed from work during acute treatment and follow-up
• Loss of future earning capacity if vision limitations restrict work activities
• Out-of-pocket expenses, including travel for specialty care
• Pain and suffering, where permitted by state law and supported by evidence
• Loss of enjoyment of life, where permitted and supported by evidence

TorHoerman Law is reviewing Victoza vision loss allegations and related GLP-1 claims, with intake focused on medical documentation, timing, and exposure records.

A case evaluation typically reviews the Victoza use history, the diagnosis and testing supporting vision loss, and whether the timeline fits the filing deadlines that apply in the relevant state.

If you used Victoza GLP 1 therapy and later experienced unexpected vision problems, you can contact TorHoerman Law for a free review or use the chatbot on this page to start the intake process.